

FORM PTO 1390
(REV 5-93)

US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NUMBER
2001_0968ATRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371U.S. APPLICATION NO.
(If known, see 37 CFR 1.52)
NEW

097/869916

International Application No.
PCT/JP00/00002International Filing Date
January 4, 2000Priority Date Claimed
January 8, 1999Title of Invention
ANTITUMOR AGENTApplicant(s) For DO/EO/US
Michiaki KOHNO and Kazushi WATANABE

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. §371(c)(2)). **ATTACHMENT A**
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19.
9. ☒ An executed oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). **ATTACHMENT B**
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

Items 11. to 14. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. **ATTACHMENT C**
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
ATTACHMENT D
13. ☒ A **FIRST** preliminary amendment. **ATTACHMENT E**
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ Other items or information:

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

U.S. APPLICATION NO. **09/869916**
NEWINTERNATIONAL APPLICATION NO.
PCT/JP00/00002JCT8 Rec'd PCT/PTO 09 JUL 2001
ATTORNEY'S DOCKET NO.
2001 0968A

15. [X] The following fees are submitted

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Neither international preliminary examination fee nor international search fee paid to USPTO
and International Search Report not prepared by the EPO or JPO \$1000.00
International Search Report has been prepared by the EPO or JPO \$ 860.00
International preliminary examination fee not paid to USPTO but international search
paid to USPTO \$ 710.00
International preliminary examination fee paid to USPTO but claims did not satisfy provisions
of PCT Article 33(1)-(4) \$ 690.00
International preliminary examination fee paid to USPTO and all claims satisfied provisions of
PCT Article 33(1)-(4) \$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS

PTO USE ONLY

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest
claimed priority date (37 CFR 1.492(e)).

\$

Claims	Number Filed	Number Extra	Rate		
Total Claims	-20 =		X \$18.00	\$	
Independent Claims	6 - 3 =	3	X \$80.00	\$240.00	
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1,100.00	
<input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.				\$	
SUBTOTAL =				\$1,100.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$
TOTAL NATIONAL FEE =				\$1,100.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property				+	\$40.00
TOTAL FEES ENCLOSED =				\$1,140.00	
				Amount to be refunded	\$
				Amount to be charged	\$

a. [X] A check in the amount of \$1,140.00 to cover the above fees is enclosed. A duplicate copy of this form is enclosed.

b. ☐ Please charge my Deposit Account No. 23-0975 in the amount of \$_____ to cover the above fees.
A duplicate copy of this sheet is enclosed.c. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 23-0975.**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or
(b)) must be filed and granted to restore the application to pending status.

19. CORRESPONDENCE ADDRESS



000513

PATENT TRADEMARK OFFICE

By: Warren M. Cheek, Jr.Warren M. Cheek, Jr.,
Registration No. 33,367WENDEROTH, LIND & PONACK, L.L.P.
2033 "K" Street, N.W., Suite 800
Washington, D.C. 20006-1021
Phone: (202) 721-8200
Fax: (202) 721-8250

July 9, 2001

[CHECK NO. 415354]

[2001_0968A]

DESCRIPTION

ANTITUMOR AGENT5 Technical Field

This invention relates to the use of a combination of a microtubule-interfering agent and an ERK-MAP kinase cascade inhibitor as an antitumor agent.

10 Background Art

Microtubules are tubular protein fibers having a diameter of about 25 nm and occurring extensively in the cells of eucaryotes such as animals, plants and fungi, and they have a wide diversity of functions covering the formation of mitotic apparatus, the develop-
15 ment and maintenance of cellular forms, flagellar and ciliary movements, the disposition of intracellular organelles, material transport, hormone secretion, the fluidity of cell membrane, and the like. Especially in nerve cells, microtubules exist as the principal constituent molecules of axons and dendrites, and contribute to material
20 transport by acting as rails for motor proteins. These microtubules are formed by the regular polymerization of the $\alpha\beta$ heterodimer of tubulin, and repeatedly show an increase or decrease by polymerization or depolymerization with the progress of the cell cycle. Moreover, the polymerization/depolymerization of these microtubules is
25 also controlled by microtubule-associated proteins (MAPs, τ protein). This control mechanism is primarily based on protein phosphorylation enzymes (kinases) and protein dephosphorylation enzymes (phosphatases) which have those microtubule-associated proteins as substrates. For these reasons, compounds acting on the microtubule
30 system (i.e., microtubule-interfering agents) exhibit various biological activities such as the inhibition of cell divisions, and are hence ex-

pected to be widely effective not only as antitumor agents, but also as fungicides, anthelmintics, herbicides and the like.

According to their mode of action, the microtubule-interfering agents are classified into compounds binding to β -tubulin and compounds binding to microtubule-associated proteins. Moreover, the compounds binding to β -tubulin are classified into compounds inhibiting the polymerization of tubulin by binding to β -tubulin, and compounds promoting the abnormal polymerization of tubulin to the contrary. In particular, the compounds inhibiting the polymerization of tubulin suppress cell divisions by inhibiting microtubule formation directly, and are hence expected to exert a selective influence on growing cells. Some such compounds are currently being used as antitumor agents, and others are under development.

On the other hand, ERK-MAP kinases are serine/threonine kinases which occur universally in eucaryotes, and play a major role in the induction of various biological phenomena (e.g., cell growth, nerve cell differentiation, cell movement acceleration, oocyte maturation, etc.) in response to diverse extracellular stimuli. That is, ERK-MAP kinases exactly play a major role in the intracellular signal transfer system where signal transfer reactions are induced by the specific binding of various cell growth/differentiation factors and the like to their respective receptors present on the surfaces of target cells.

In the aforesaid intracellular signal transfer system (i.e., the ERK-MAP kinase cascade), several signal molecules are known to function on the upstream side of the ERK-MAP kinases. The molecules which have been most fully analyzed include Ras, Raf-1, MEK and the like. Specifically, Ras, a GTP-binding protein, is activated in response to external various stimuli. Then, Raf-1 (serine/threonine kinase), which is a sort of MAP kinase kinase kinase (MAPKKK), is activated. Subsequently, Raf-1 phosphorylates/activates MEK1/2 that

is a sort of MAP kinase kinase having a unique substrate specificity capable of phosphorylating both serine/threonine residues and tyrosine residues. The activated MEK1/2 converts an inactive form of MAP kinases (ERK1/2) to an active form of MAP kinase by the phosphorylation of T (threonine) and Y (tyrosine) residues in the Thr-Glu-Tyr (TEY) sequence which is present between the subdomains VII and VIII of the kinases. It is believed that the MAP kinases (ERK1/2) activated in the above-described manner migrates from the cytoplasm to the nucleus, where it induces the phosphorylation/activation of several transcription factors and thereby leads to the induction of a final physiological response. As described above, the ERK-MAP kinase cascade is known to participate in the expression of various physiological responses. In particular, it has been clarified that the ERK-MAP kinase cascade plays an essential role in the promotion of cell growth. In other words, it is expected that cell growth can be suppressed by blocking the ERK-MAP kinase cascade.

However, the effectiveness of antitumor agents comprising a combination of a compound acting on microtubules and a compound blocking the ERK-MAP kinase cascade, as described above, has been utterly unknown as yet.

Disclosure of the Invention

Now, as a result of various investigations on the antitumor effect of microtubule-interfering agents, the present inventors have quite unexpectedly found that, when a microtubule-interfering agent having an antitumor effect is used in combination with an ERK-MAP kinase cascade inhibitor, the antitumor effect of the microtubule-interfering agent is remarkably potentiated.

Thus, according to the present invention, there is provided a combination of a microtubule-interfering agent and an ERK-MAP kinase cascade inhibitor wherein the microtubule-interfering agent

and the ERK-MAP kinase cascade inhibitor are administered, either simultaneously or separately with a predetermined interval of time, in order to treat tumors.

According to the present invention, there is also provided
5 an antitumor agent which contains, as an active ingredient, a microtubule-interfering agent for use in combination with an ERK-MAP kinase cascade inhibitor.

According to the present invention, there is also provided
an agent for potentiating the antitumor effect of a microtubule-
10 interfering agent which contains an ERK-MAP kinase cascade inhibitor as an active ingredient.

According to the present invention, there is also provided
a method for the treatment of a tumor which comprises administering
a microtubule-interfering agent and an ERK-MAP kinase cascade
15 inhibitor to a patient, either simultaneously or separately with a predetermined interval of time.

Moreover, according to the present invention, there is
provided a method for the use of an ERK-MAP kinase cascade inhibitor for the purpose of potentiating the antitumor effect of a
20 microtubule-interfering agent.

Furthermore, according to the present invention, there is
provided a pharmaceutical product comprising a microtubule-interfering agent and/or an ERK-MAP kinase cascade inhibitor, the pharmaceutical product being characterized by having, on or within the
25 packaging material thereof, an indication or document showing the instruction that the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor should be used in combination.

The term "microtubule-interfering agent" as used herein
means any drug that acts on the microtubule system and thereby
30 exhibits an antitumor effect. According to their site of action, they are classified into compounds binding to β -tubulin and compounds

0986916-070904
T06020-9T59250

binding to microtubule-associated proteins. Moreover, the compounds binding to β -tubulin are classified into compounds inhibiting the polymerization of tubulin by binding to β -tubulin and compounds promoting the abnormal polymerization of tubulin to the contrary.

- 5 Specifically, the compounds inhibiting the polymerization of tubulin include, for example, dolastatin 10 and compounds analogous thereto, vincristine and compounds analogous thereto, maytansine (THE MERCK INDEX 12th EDITION No. 5800), rhizoxin, phomopsin, ustiloxin and combrestatin. The compounds promoting the polymer-
10 ization of tubulin include, for example, paclitaxel (THE MERCK INDEX 12th EDITION No. 7117), docetaxel, Taxotere and taxuspine.

- On the other hand, the compounds binding to microtubule-associated proteins include, for example, griseofulvin (THE MERCK INDEX 12th EDITION No. 4571) and estramustine (THE MERCK
15 INDEX 12th EDITION No. 3749).

- The compound which can be preferably used as microtubule-interfering agents in the present invention are compounds inhibiting the polymerization of tubulin. Among them, dolastatin 10 and compounds analogous thereto, and vincristine and compounds
20 analogous thereto are especially preferred.

- Specific examples of these dolastatin 10 and compounds analogous thereto include, for example, the compounds described in references such as Japanese Patent Laid-Open No. 167278/'90, PCT International Publication WO93/03054 Pamphlet, PCT International
25 Publication WO95/09864 Pamphlet, PCT International Publication WO96/33212 Pamphlet, Japanese Patent Laid-Open No. 293795/'94, Japanese Patent Laid-Open No. 70173/'95, Japanese Patent Laid-Open No. 59693/'96, Japanese Patent Laid-Open No. 81493/'96, Japanese Patent Laid-Open No. 119990/'96, Japanese Patent Laid-Open No.
30 188594/'96, Japanese Patent Laid-Open No. 77791/'97, Published Japanese Translation of PCT International Publication No. 506580/'95,


and Published Japanese Translation of PCT International Publication
No. 504415/96.

Among these dolastatin 10 and compounds analogous
thereto, the following compound (hereinafter referred to as "TZT-
5 1027") is especially preferred.

N²-(N,N-Dimethyl-L-valyl)-N-[(1S,2R)-2-methoxy-4-
[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)-
amino]propyl]-1-pyrrolidiny]-1-[(S)-1-methylpropyl]-4-oxobutyl]-N-
methyl-L-valinamide.

10

15



[TZT-1027]

Specific examples of vincristine and compounds analogous
20 thereto include, for example, vincristine (THE MERCK INDEX 12th
EDITION No. 10124), vinblastine (THE MERCK INDEX 12th EDI-
TION No. 10119), and vindesine (THE MERCK INDEX 12th EDITION
No. 10125).

The term "ERK-MAP kinase cascade inhibitor" as used
25 herein means any compound that acts on a particular molecule in the
ERK-MAP kinase cascade and eventually prevents MAP kinase from
exhibiting its action effectively. Theoretically, this term comprehends
all of the compounds which inhibit the action of MAPKKK and thereby
prevent activated MAP kinase kinase from being effectively formed,
30 the compounds which inhibit the action of activated MAP kinase
kinase and thereby prevent activated MAP kinase from being effec-

tively formed, and the compounds which inhibit the action of activated MAP kinase.

Specific examples of these ERK-MAP kinase cascade inhibitors include, for example, 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one (hereinafter referred to as "PD98059"; Proc. Natl. Acad. Sci., Vol. 92, pp. 7686-7689, 1995), 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (hereinafter referred to as "U1026"; J. Biol. Chem., Vol. 273, pp. 18623-18632, 1998), and 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide (hereinafter referred to as "PD1843522"; Nature Medicine, Vol. 5, pp. 810-816, 1999).

If necessary, the microtubule-interfering agent or ERK-MAP kinase cascade inhibitor used in the present invention may be reacted with an inorganic or organic acid or an inorganic or organic base to form a pharmaceutically acceptable salt. The inorganic acids which can be used to form a salt include, for example, hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and phosphoric acid, and the organic acids which can be used include, for example, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, lactic acid, malic acid, tartaric acid, citric acid, benzoic acid and methanesulfonic acid. On the other hand, the inorganic bases which can be used to form a salt include, for example, sodium hydroxide, ammonium hydroxide, calcium carbonate, sodium hydrogen carbonate and calcium hydroxide, and the organic bases which can be used include, for example, methylamine, diethylamine, cyclohexylamine, ethanolamine and morpholine.

The above-described microtubule-interfering agent and ERK-MAP kinase cascade inhibitor may be used in the form of a pharmaceutical preparation having any of dosage forms including solid forms (e.g., tablets, hard capsules, soft capsules, granules, powders, fine subtilaes, pills and troches), semisolid forms (e.g.,

suppositories and ointments), and liquid forms (e.g., injections, emulsions, suspensions, elixirs, lotions and sprays). The additives which can be used to make such pharmaceutical preparations include, for example, starch, glucose, sucrose, lactose, fructose, maltose, mannitol, sorbitol, cyclodextrin, silicic acid derivatives, methylcellulose, carboxymethylcellulose and its salts, alginates, gelatin, polyvinyl pyrrolidone, calcium carbonate, sodium hydrogen carbonate, magnesium carbonate, talc, magnesium stearate, gum arabic, polyethylene glycol, alkyl p-hydroxybenzoates, cetyl alcohol, syrups, ethanol, propylene glycol, vaseline, carbowax, glycerol, sodium chloride, sodium sulfite, sodium phosphate, citric acid, lactic acid, sodium hydroxide, polylactic acid and polylactic acid-glycolic acid.

The above-described pharmaceutical preparations may be such that both of the active ingredients (i.e., the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor) are contained in a single pharmaceutical preparation, or such that the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor are formed into separate pharmaceutical preparations.

In the present invention, so long as the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor are administered in combination, they may be administered either simultaneously or separately with a predetermined interval of time. Thus, the method of administration may be suitably chosen according to the doctor's diagnosis, the symptoms of the patient, and the like. Where the active ingredients are administered separately, it is generally desirable to administer the ERK-MAP kinase cascade inhibitor in advance.

Moreover, in the present invention, pharmaceutical products comprising the microtubule-interfering agent and/or the ERK-MAP kinase cascade inhibitor are preferably characterized by having, on or within the packaging material thereof, an indication or docu-

ment showing instructions for the combined use of the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor.

The contents of the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor in the pharmaceutical preparations of the present invention may vary according to their dosage form and the like. However, it is generally desirable that the pharmaceutical preparations contain each drug at a concentration of 0.1 to 50% by weight in the case of solid and semisolid forms, and at a concentration of 0.05 to 10% by weight in the case of liquid forms.

The dosages of the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor may vary widely according to the route of administration, the type and severity of symptoms, the doctor's diagnosis, and the like. However, the generally acceptable effective dose of the microtubule-interfering agent may be in the range of about 0.1 to about 1,000 mg per treatment and preferably about 0.5 to about 500 mg per treatment. The generally acceptable effective dose of the ERK-MAP kinase cascade inhibitor may be in the range of about 0.1 to about 1,000 mg per treatment and preferably about 50 to about 500 mg per treatment.

Nevertheless, it is a matter of course that, depending on the type and severity of symptoms and the doctor's diagnosis as described above, each of the drugs may be administered in a dose less than the lower limit of the aforesaid range or greater than the upper limit thereof. The aforesaid doses of the drugs may be administered at intervals of several hours to one month.

Examples

The present invention is more specifically explained with reference to the following tests and examples.

Tests

In the following tests, TZT-1027 or vincristine was used as the microtubule-interfering agent, and PD98059 was used as the ERK-

MAP kinase cascade inhibitor.

1. Preparation of samples

DMEM medium containing 10% fetal bovine serum was placed in plastic culture dishes having a diameter of 6 cm. Then, 5 WiDr cells (obtained from HSRRB), which were human colon carcinoma cells, were inoculated therein so as to give a density of 2.0×10^5 cells/3 mL. These culture dishes were incubated at 37°C for 48 hours. Moreover, 1/1000 volume of PD98059 (with a final concentration of 50 $\mu\text{mol/L}$) or solvent (DMSO) was added thereto, followed by 10 incubation for 12 hours. Thereafter, 1/1000 volume of TZT-1027 (with a final concentration of 10 nmol/L) or solvent (a lactic acid buffer) was added thereto. Where vincristine was used as the microtubule-interfering agent, 1/1000 volume of vincristine sulfate (with a final concentration of 100 nmol/L) or solvent (DMSO) was added thereto. 15 Twenty-four (24), 48, 72 or 96 hours after the addition of TZT-1027, vincristine or solvent, cells were collected and worked up according to the following procedure. With respect to a solvent control group and a group treated with PD98059 alone, cells were similarly collected and worked up after 96 hours' incubation.

20 First of all, all of the culture medium was transferred to a centrifuge tube. The remaining cells were suspended by adding 1 mL of a 0.05% trypsin/phosphate-buffered physiological saline (PBS)-EDTA solution to the culture dish and incubating it at 37°C for 5 minutes, and combined with the above culture medium. The centri- 25 fuge tube was centrifuged at 1,500 rpm for 5 minutes. Then, the precipitate was resuspended in 1 mL of PBS, transferred to a light-shielding microtube, and centrifuged at 2,500 rpm for 5 minutes. After the precipitate was suspended in 60 μL of PBS, 140 μL of 100% ethanol was added thereto and the resulting suspension was stirred 30 and allowed to stand at -20°C overnight or longer. Moreover, the suspension was centrifuged at 2,500 rpm for 5 minutes, and 100 μL of

5 a phosphate-citric acid buffer (0.2M Na_2PO_4 : 0.1M citric acid = 24:1) was added to the precipitate, followed by stirring (at 500 rpm) at room temperature for 30 minutes. After suspension was centrifuged at 2,500 rpm for 5 minutes, 100 μL of PBS and 1 μL of an RNase solution (10 mg/mL (PBS); obtained from SIGMA) was added to the precipitate, followed by incubation at 37°C for 30 minutes. Thereafter, 880 μL of PBS and 20 μL of a propidium iodide (hereinafter referred to as "PI") solution (1 mg/mL (PBS); obtained from Wako Pure Chemical Industries Ltd.) were added thereto and reacted at room temperature for 30 minutes with stirring. The resulting reaction mixture was allowed to stand in the dark under cooling with ice until it was used for measurement.

2. Cell death rate

15 The cell death rate was measured and analyzed by means of an EPICS XL system (manufactured by COULTER). Prior to analysis, the EPICS XL system was checked by means of DNACheck (manufactured by COULTER).

Next, a protocol used for calculating the cell death rate by using the DNA content as a parameter was constructed. In this protocol, FS (forward scatter), SS (side scatter) and FL3 (PI fluorescence) were selected as parameters, and the number of analyzed cells was 30,000. Furthermore, by measuring a control sample of cells to be actually measured, the sensitivity of the detector and regions were preset with consideration for each parameter. Measurements were made by pipetting a sample at several times, transferring it into an exclusive tube, and setting it in the main unit of the EPICS XL system. The cell death rate was calculated by use of histograms in the protocol, which were constructed by removing doublets and triplets from data incorporating dead cells. The results of the measurements are shown in Table 1 below.

Table 1

	<u>Microtubule interfering-agent</u>	<u>ERK-MAP kinase cascade inhibitor</u>	<u>Time</u>	<u>Cell death rate (%)</u>
5	None (lactic acid buffer)	None (0.1% DMSO)	96	3.0
	None (lactic acid buffer)	PD98059 (50 μ mol/L)	96	8.9
	TZT-1027 (10 nmol/L)	None (treated with the solvent alone)	24	3.8
			48	9.2
			96	23.3
10	TZT-1027 (10 nmol/L)	PD98059 (50 μ mol/L)	24	10.5
			48	35.9
			96	48.1
	Vincristine (100 nmol/L)	None (treated with the solvent alone)	24	4.5
			48	8.4
			72	23.3
15	Vincristine (100 nmol/L)	PD98059 (50 μ mol/L)	24	12.1
			48	37.4
			72	58.7

Example 1

20 Injection:

		<u>mg/ampule</u>
	Active component	TZT-1027
		0.2
	Tonicity agent	Sodium chloride
		q.s.
	pH regulator	Lactic acid
		q.s.
25	pH regulator	Sodium hydroxide
		q.s.
	Solvent	Water for injection
		q.s.
		1 mL

30 Sodium chloride and lactic acid are dissolved in water for injection, and the active ingredient is dissolved in the resulting solution. After the pH of the solution is adjusted to 4-5 with sodium hydroxide, water for injection is added thereto until the prescribed

volume is reached.

Tablets:

	<u>mg/tablet</u>
PD98059	20.0
5 Starch	5.0
Lactose	132.0
Carboxymethylcellulose calcium	10.0
Talc	1.0
Magnesium stearate	2.0
10	170.0

PD98059 is pulverized to a particle size of 70 microns or less. Then, starch, lactose and carboxymethylcellulose calcium are added thereto and thoroughly mixed therewith. After the addition of 15 10% starch paste, the above powder mixture is agitated and blended to prepare granules. After drying, these granules are adjusted to a particle diameter of about 1,000 microns, and mixed with talc and magnesium stearate. The resulting mixture is formed into tablets.

1000000-070000

CLAIMS

1. A combination of a microtubule-interfering agent and an ERK-MAP kinase cascade inhibitor wherein the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor are administered, either simultaneously or separately with a predetermined interval of time, in order to treat a tumor.
2. A combination as claimed in claim 1 wherein the microtubule-interfering agent is a tubulin polymerization inhibitor.
3. A combination as claimed in claim 2 wherein the tubulin polymerization inhibitor is dolastatin 10 or a compound analogous thereto, or vincristine or a compound analogous thereto.
4. A combination as claimed in claim 1 wherein the ERK-MAP kinase cascade inhibitor is a MAP kinase inhibitor, a MAP kinase inhibitor or a MAP kinase kinase inhibitor.
5. An antitumor agent which contains, as an active ingredient, a microtubule-interfering agent for use in combination with an ERK-MAP kinase cascade inhibitor.
6. An agent for potentiating the antitumor effect of a microtubule-interfering agent which contains an ERK-MAP kinase cascade inhibitor as an active ingredient.
7. A method for the treatment of a tumor which comprises administering a microtubule-interfering agent and an ERK-MAP kinase cascade inhibitor to a patient, either simultaneously or separately with a predetermined interval of time.
8. The use of an ERK-MAP kinase cascade inhibitor for the purpose of potentiating the antitumor effect of a microtubule-interfering agent.
9. A pharmaceutical product comprising a microtubule-interfering agent and/or an ERK-MAP kinase cascade inhibitor, the pharmaceutical product being characterized by having, on or within

the packaging material thereof, an indication or document showing the instruction that the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor should be used in combination.

09269916-070901

ABSTRACT

When a microtubule-interfering agent having an antitumor effect is used in combination with an ERK-MAP kinase cascade inhibitor, the antitumor effect of the microtubule-interfering agent is remarkably potentiated. Accordingly, a combination of a microtubule-interfering agent and an ERK-MAP kinase cascade inhibitor is useful as a very effective antitumor agent.

T06070" 9T559850

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Michiaki KOHNO et al. : Attn: BOX PCT
Serial No. NEW : Docket No. 2001_0968A
Filed July 9, 2001 :

ANTITUMOR AGENT
[Corresponding to PCT/JP00/00002
Filed January 4, 2000]

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Prior to calculating the filing fee, please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, line 4 after the title, please insert the following:

This application is a 371 of PCT/JP00/00002 filed January 4, 2000.

Page 4, the paragraph beginning at line 28, please replace with the following paragraph:

The term "microtubule-interfering agent" as used herein means any drug that acts on the microtubule system and thereby exhibits an antitumor effect. According to their site of action, they are classified into compounds binding to β -tubulin and compounds binding to microtubule-associated proteins. Moreover, the compounds binding to β -tubulin are classified into compounds inhibiting the polymerization of tubulin by binding to β -tubulin and compounds promoting the abnormal polymerization of tubulin to the contrary. Specifically, the compounds inhibiting the

09/869916-07001

polymerization of tubulin include, for example, dolastatin 10 and compounds analogous thereto, vincristine and compounds analogous thereto, maytansine (THE MERCK INDEX 12th EDITION No. 5800), rhizoxin, phomopsin, ustiloxin and combrestatin. The compounds promoting the polymerization of tubulin include, for example, paclitaxel (THE MERCK INDEX 12th EDITION No. 7117), docetaxel and taxuspine.

Page 7, the paragraph beginning at line 3, please replace with the following:

Specific examples of these ERK-MAP kinase cascade inhibitors include, for example, 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one (hereinafter referred to as "PD98059"; Proc. Natl. Acad. Sci., Vol. 92, pp. 7686-7689, 1995), 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (hereinafter referred to as "U1026"; J. Biol. Chem., Vol. 273, pp. 18623-18632, 1998), and 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide (hereinafter referred to as "PD184352"; Nature Medicine, Vol. 5, pp. 810-816, 1999).

T06040"9T69660

REMARKS

The foregoing amendments amend the specification to reflect the 371 status. In addition, minor amendments have been effected to the specification.

On page 5, line 11, the compound "Taxotere" is deleted because Taxotere is the trade name for docetaxel which is described on the same line. On page 7, line 10, a minor typographical error has been corrected.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached pages are captioned "**Version with markings to show changes made**".

Favorable Action on the merits is solicited.

Respectfully submitted,

Michiaki KOHNO et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 9, 2001

DESCRIPTION

ANTITUMOR AGENT

✓ This application is a 371 of PCT/JP00/00002 filed January 4, 2000.

5 Technical Field

This invention relates to the use of a combination of a microtubule-interfering agent and an ERK-MAP kinase cascade inhibitor as an antitumor agent.

10 Background Art

Microtubules are tubular protein fibers having a diameter of about 25 nm and occurring extensively in the cells of eucaryotes such as animals, plants and fungi, and they have a wide diversity of functions covering the formation of mitotic apparatus, the develop-
15 ment and maintenance of cellular forms, flagellar and ciliary move-
ments, the disposition of intracellular organellas, material transport, hormone secretion, the fluidity of cell membrane, and the like. Especially in nerve cells, microtubules exist as the principal constitu-
ent molecules of axons and dendrites, and contribute to material
20 transport by acting as rails for motor proteins. These microtubules are formed by the regular polymerization of the $\alpha\beta$ heterodimer of tubulin, and repeatedly show an increase or decrease by polymeriza-
tion or depolymerization with the progress of the cell cycle. More-
over, the polymerization/depolymerization of these microtubules is
25 also controlled by microtubule-associated proteins (MAPs, τ protein). This control mechanism is primarily based on protein phosphorylation enzymes (kinases) and protein dephosphorylation enzymes (phos-
phatases) which have those microtubule-associated proteins as sub-
strates. For these reasons, compounds acting on the microtubule
30 system (i.e., microtubule-interfering agents) exhibit various biological activities such as the inhibition of cell divisions, and are hence ex-

T06020" 9T659260

binding to microtubule-associated proteins. Moreover, the compounds binding to β -tubulin are classified into compounds inhibiting the polymerization of tubulin by binding to β -tubulin and compounds promoting the abnormal polymerization of tubulin to the contrary.

- 5 Specifically, the compounds inhibiting the polymerization of tubulin include, for example, dolastatin 10 and compounds analogous thereto, vincristine and compounds analogous thereto, maytansine (THE MERCK INDEX 12th EDITION No. 5800), rhizoxin, phomopsin, ustiloxin and combrestatin. The compounds promoting the polymer-
10 ization of tubulin include, for example, paclitaxel (THE MERCK
✓ INDEX 12th EDITION No. 7117), docetaxel, ~~Taxotere~~ and taxuspine.

- On the other hand, the compounds binding to microtubule-associated proteins include, for example, griseofulvin (THE MERCK INDEX 12th EDITION No. 4571) and estramustine (THE MERCK
15 INDEX 12th EDITION No. 3749).

- The compound which can be preferably used as microtubule-interfering agents in the present invention are compounds inhibiting the polymerization of tubulin. Among them, dolastatin 10 and compounds analogous thereto, and vincristine and compounds
20 analogous thereto are especially preferred.

- Specific examples of these dolastatin 10 and compounds analogous thereto include, for example, the compounds described in references such as Japanese Patent Laid-Open No. 167278/'90, PCT International Publication WO93/03054 Pamphlet, PCT International
25 Publication WO95/09864 Pamphlet, PCT International Publication WO96/33212 Pamphlet, Japanese Patent Laid-Open No. 293795/'94, Japanese Patent Laid-Open No. 70173/'95, Japanese Patent Laid-Open No. 59693/'96, Japanese Patent Laid-Open No. 81493/'96, Japanese Patent Laid-Open No. 119990/'96, Japanese Patent Laid-Open No.
30 188594/'96, Japanese Patent Laid-Open No. 77791/'97, Published Japanese Translation of PCT International Publication No. 506580/'95,

09669916-070903
T06020-9T669860

tively formed, and the compounds which inhibit the action of activated MAP kinase.

Specific examples of these ERK-MAP kinase cascade inhibitors include, for example, 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one (hereinafter referred to as "PD98059"; Proc. Natl. Acad. Sci., Vol. 92, pp. 7686-7689, 1995), 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (hereinafter referred to as "U1026"; J. Biol. Chem., Vol. 273, pp. 18623-18632, 1998), and 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide (hereinafter referred to as "PD184352"; Nature Medicine, Vol. 5, pp. 810-816, 1999).

If necessary, the microtubule-interfering agent or ERK-MAP kinase cascade inhibitor used in the present invention may be reacted with an inorganic or organic acid or an inorganic or organic base to form a pharmaceutically acceptable salt. The inorganic acids which can be used to form a salt include, for example, hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and phosphoric acid, and the organic acids which can be used include, for example, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, lactic acid, malic acid, tartaric acid, citric acid, benzoic acid and methanesulfonic acid. On the other hand, the inorganic bases which can be used to form a salt include, for example, sodium hydroxide, ammonium hydroxide, calcium carbonate, sodium hydrogen carbonate and calcium hydroxide, and the organic bases which can be used include, for example, methylamine, diethylamine, cyclohexylamine, ethanolamine and morpholine.

The above-described microtubule-interfering agent and ERK-MAP kinase cascade inhibitor may be used in the form of a pharmaceutical preparation having any of dosage forms including solid forms (e.g., tablets, hard capsules, soft capsules, granules, powders, fine subtilaes, pills and troches), semisolid forms (e.g.,

DECLARATION AND POWER OF ATTORNEY FOR U. S. PATENT APPLICATION

☒ Original ☐ Supplemental ☐ Substitute ☐ PCT ☐ Design

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: ANTITUMOR AGENT

of which is described and claimed in:

☐ the attached specification, or☐ the specification in the application Serial No. _____ filed _____;

and with amendments through _____ (if applicable), or

☒ the specification in International Application No. PCT/JP00/00002, filed Jan. 4, 2000, and as amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:


COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	2971/99	January 8, 1999	Yes

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS. PATENTED, PENDING, ABANDONED

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Warren M. Cheek, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; Charles R. Watts, Reg. No. 33,142; and Michael S. Huppert, Reg. No. 40,268, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., as well as any other attorneys and agents associated with Customer No. 000513, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys and agents named herein to accept and follow instructions from ODAJIMA & CO. as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Direct Correspondence to Customer No.  000513 PATENT TRADEMARK OFFICE	Direct Telephone Calls to: WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N. W., Suite 800 Washington, D C. 20006 Phone: (202) 721-8200 Fax: (202) 721-8250
--	---

Full Name of First Inventor	FAMILY NAME <u>KOHNO</u>	FIRST GIVEN NAME <u>Michiaki</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Nagasaki-shi</u>	STATE OR COUNTRY <u>Nagasaki-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>
Post Office Address	<u>19-1-503, Yanagawa-machi, Nagasaki-shi, NAGASAKI</u> <u>JPX</u> <u>852-8013 JAPAN</u>		
Full Name of Second Inventor	FAMILY NAME <u>WATANABE</u>	FIRST GIVEN NAME <u>Kazushi</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Kawasaki-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>
Post Office Address	<u>5-14-6-32, Kamikodanaka, Nakahara-ku, Kawasaki-shi,</u> <u>KANAGAWA 211-0053 JAPAN</u> <u>JPX</u>		
Full Name of Third Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address			
Full Name of Fourth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address			

TELEPHONE

Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address			

Full Name of Sixth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address			

Full Name of Seventh Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address			


I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Michiaki Kohno Date June 25, 2001
 2nd Inventor Kazushi Watanabe Date June 25, 2001
 3rd Inventor _____ Date _____
 4th Inventor _____ Date _____
 5th Inventor _____ Date _____
 6th Inventor _____ Date _____
 7th Inventor _____ Date _____

The above application may be more particularly identified as follows:

U.S. Application Serial No. _____ Filing Date _____
 Applicant Reference Number _____ Atty Docket No. _____
 Title of Invention _____

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☒ Page(s) 6, of Description were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ *Scanned copy is best available.*

FD-602 (2-9-85)